Novel RNase-based Immunotoxin for CD74-positive B-cell Malignancies

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$134,285.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA121468-01A1
Award Id:
85382
Agency Tracking Number:
CA121468
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
300 AMERICAN ROAD, MORRIS PLAINS, NJ, 07950
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
115350605
Principal Investigator:
CHIENHSING CHANG
(973) 605-1330
KCHANG@IMMUNOMEDICS.COM
Business Contact:
() -
pparker@immunomedics.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): This is an amended application of 1 R43 CA121468-01, which was originally submitted on July 29, 2005. Immunomedics, Inc. has developed a series of recombinant immunotoxins that are composed of two molecules of ranpirnas e (Rap), an amphibian ribonuclease (RNase), each fused to the N- terminus of the light (L) chain of an internalizing humanized IgG. The first of such immunotoxins, 2L-Rap-hLL1-gamma4P, was constructed to target CD74-expressing tumors for killing by fused R ap via the rapidly internalizing anti-CD74 humanized antibody hLL1, and has demonstrated potent anti-tumor activity in human Burkitt lymphoma xenograft models (Chang CH, et al., Effective therapy of human lymphoma xenografts with a novel recombinant ribonu clease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood, 2005, 106: 4308-431). Because the wild-type Rap in 2L- Rap- hLL1-gamma4P is glycosylated, the success of 2L- Rap-hLL1-gamma4P prompted us to generate 2L- Rap(N69Q)-hLL1-gamma4P, which contains th e non-glycosylated variant of Rap, but is otherwise equivalent to 2L-Rap-hLL1-gamma4P in many attributes, including all in vitro properties evaluated, in vivo liver toxicity, and anti-tumor activity in SCID mice bearing Daudi lymphoma xenografts. In this a pplication, we propose to pursue further preclinical development of 2L-Rap(N69Q)-hLL1-gamma4P as a potential therapeutic for treating CD74-positive cancers, in particular, multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Specifically, we will evaluate 2L-Rap(N69Q)-hLL1-gamma4P for anti-tumor efficacy in SCID mice bearing MM or NHL human tumor xenografts with a single-dose or multiple-dose regimen. We will also address the observed nonspecific liver toxicity by investigating whether the hepatotoxicity c ould be related to the high pI of the immunotoxin and examining whether anti- inflammatory agents could be effective in reducing such liver injury. A further goal is to amplify the production clone to increase yields and adapt the fully amplified clone to grow in serum-free conditions. Upon completing these studies, we should be able to define the therapeutic window of 2L-Rap-hLL1 (N69Q)-gamma4P in SCID mice models bearing human NHL or MM xenografts, and produce 2L-Rap-hLL1 (N69Q)-gamma4P in large scale for GLP Pharmacology/Toxicology studies in cynomolgus monkeys to obtain data for supporting the submission of a phase I clinical IND for treating patients with recurrent or refractory MM or NHL.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government